- Public Library of Science
- Nature Magazine
- Vaccine
- Cell
- New England Journal of Medicine

Vaccine Development for SARS-CoV References by Journal 

A study showed that SARS neutralizing antibodies can successfully block SARS-CoV-2 entry into target cells in vitro, suggesting that the two viruses possess a cross-protective epitope and have similar immune protection against reinfection

SARS neutralizing antibodies and SARS-CoV-2


- Philosophical transactions of the Royal Society of London. Series B, Biological sciences
- The Lancet

Epidemiology and Transmission Dynamics of SARS-CoV References by Journal

The epidemiological study and transmission dynamics of the 2002-2003 SARS-CoV epidemic can be classified into several key areas: the viral agent, environmental factors, superspreader events, specific transmission dynamics (such as incubation and infectious periods), and the chronological progression of the outbreak's first and second waves.

Epidemiology and Transmission Dynamics of SARS-CoV

This classification groups learning nodes based on two vaccine-development articles: a SARS-CoV vaccine-challenge study on pulmonary immunopathology and a report on four Latin American COVID-19 vaccine-manufacturing approaches.

Selected Articles on SARS-CoV and COVID-19 Vaccine Development

This classification organizes antibody-response references for SARS-CoV and SARS-CoV-2 by publication source: PLOS ONE, The Lancet, CDC, the New England Journal of Medicine, the Journal of Infectious Diseases, the Journal of Immunology, JAMA Network, and medRxiv.

Sources for SARS-CoV and SARS-CoV-2 Antibody-Response References

- Vaccine Development
- Antibody immune response
- Epidemiology and transmission dynamics 

Syracuse University

Saint Louis University

University of Michigan - Ann Arbor

SARS-CoV, or SARS-associated coronavirus, is a virus that causes Severe Acute Respiratory Syndrome (SARS), which first appeared in 2003 and spread around the world. SARS-CoV is considered a select agent, meaning it has the potential to severely threathen public health.

SARS-CoV

This virus uses angiotensin-converting enzyme 2 (ACE2) as a functional cellular receptor.
The virus also binds to the C-type lectin CD209L (also known as L-SIGN) and DC-SIGN

Learn Before

Related

Learn After